Inhibiting endothelial factors (e.g., FASL) increases CD8+ infiltration and suppresses tumour growth, revealing an endothelial immune barrier and offering a therapeutic avenue for improving anti-tumour immunity [480]. This evidence concerns the gene FASLG and neoplasm.